ORAGRAFIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oragrafin Sodium, and when can generic versions of Oragrafin Sodium launch?
Oragrafin Sodium is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in ORAGRAFIN SODIUM is ipodate sodium. There is one drug master file entry for this compound. Additional details are available on the ipodate sodium profile page.
Summary for ORAGRAFIN SODIUM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 61 |
Patent Applications: | 1,052 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORAGRAFIN SODIUM at DailyMed |
US Patents and Regulatory Information for ORAGRAFIN SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | ORAGRAFIN SODIUM | ipodate sodium | CAPSULE;ORAL | 012967-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |